Disclosures for "Neutrophil-to-lymphocyte ratio as a biomarker for Guillain-Barré Syndrome: A systematic review with meta-analysis")
-
Mr. Cabanillas Lazo has nothing to disclose.
-
Mr. Vicuña has nothing to disclose.
-
Miss Cruzalegui Bazán has nothing to disclose.
-
Miss Pascual-Guevara has nothing to disclose.
-
Dr. Mori has received personal compensation in the range of $0-$499 for serving as a Consultant for Roche. Dr. Mori has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Mori has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Mori has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sanofi.
-
Carlos Alva-Diaz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Farma. Carlos Alva-Diaz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche Farma. The institution of Carlos Alva-Diaz has received research support from Roche farma.